RBC Capital slightly trimmed Vertex Pharmaceuticals’ price target from $423 to $420, but the firm’s rating stayed the course.

This was the stock's third consecutive day of losses.

Dottie Caplan, who previously served as Senior Vice President, Patient Advocacy and Engagement, will be responsible for leading Applied’s patient engagement and advocacy efforts as well as the ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant ...

Nearly $30 million in tax incentive awards are expected to add 1,519 new life sciences jobs in Massachusetts, with about 52% ...

Major global pharmaceutical companies traded lower in the premarket on Tuesday after President Donald Trump reiterated his ...

Chronic low back pain (CLBP) is a widespread and long-lasting condition defined by lower back pain that lasts for at least 12 weeks. The l ...